221 related articles for article (PubMed ID: 1988718)
1. Uptake of 2-deoxy, 2-(18F) fluoro-D-glucose in bladder cancer: animal localization and initial patient positron emission tomography.
Harney JV; Wahl RL; Liebert M; Kuhl DE; Hutchins GD; Wedemeyer G; Grossman HB
J Urol; 1991 Feb; 145(2):279-83. PubMed ID: 1988718
[TBL] [Abstract][Full Text] [Related]
2. Preliminary assessment of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with bladder cancer.
Kosuda S; Kison PV; Greenough R; Grossman HB; Wahl RL
Eur J Nucl Med; 1997 Jun; 24(6):615-20. PubMed ID: 9169567
[TBL] [Abstract][Full Text] [Related]
3. Comparison of 11C-choline with 18F-FDG in positron emission tomography/computerized tomography for staging urothelial carcinoma: a prospective study.
Golan S; Sopov V; Baniel J; Groshar D
J Urol; 2011 Aug; 186(2):436-41. PubMed ID: 21679983
[TBL] [Abstract][Full Text] [Related]
4. Preoperative lymph-node staging of invasive urothelial bladder cancer with 18F-fluorodeoxyglucose positron emission tomography/computed axial tomography and magnetic resonance imaging: correlation with histopathology.
Jensen TK; Holt P; Gerke O; Riehmann M; Svolgaard B; Marcussen N; Bouchelouche K
Scand J Urol Nephrol; 2011 Mar; 45(2):122-8. PubMed ID: 21231796
[TBL] [Abstract][Full Text] [Related]
5. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose.
Avril N; Dose J; Jänicke F; Ziegler S; Römer W; Weber W; Herz M; Nathrath W; Graeff H; Schwaiger M
J Natl Cancer Inst; 1996 Sep; 88(17):1204-9. PubMed ID: 8780629
[TBL] [Abstract][Full Text] [Related]
6. Fluorodeoxyglucose-positron emission tomography in the detection and staging of lung cancer.
Sazon DA; Santiago SM; Soo Hoo GW; Khonsary A; Brown C; Mandelkern M; Blahd W; Williams AJ
Am J Respir Crit Care Med; 1996 Jan; 153(1):417-21. PubMed ID: 8542152
[TBL] [Abstract][Full Text] [Related]
7. Is [F-18]-fluorodeoxyglucose FDG-PET/CT better than ct alone for the preoperative lymph node staging of muscle invasive bladder cancer?
Uttam M; Pravin N; Anish B; Nandita K; Arup M
Int Braz J Urol; 2016; 42(2):234-41. PubMed ID: 27256176
[TBL] [Abstract][Full Text] [Related]
8. Cancer detection with whole-body PET using 2-[18F]fluoro-2-deoxy-D-glucose.
Hoh CK; Hawkins RA; Glaspy JA; Dahlbom M; Tse NY; Hoffman EJ; Schiepers C; Choi Y; Rege S; Nitzsche E
J Comput Assist Tomogr; 1993; 17(4):582-9. PubMed ID: 8331230
[TBL] [Abstract][Full Text] [Related]
9. Lymph node staging in non-small cell lung cancer: evaluation by [18F]FDG positron emission tomography (PET).
Guhlmann A; Storck M; Kotzerke J; Moog F; Sunder-Plassmann L; Reske SN
Thorax; 1997 May; 52(5):438-41. PubMed ID: 9176535
[TBL] [Abstract][Full Text] [Related]
10. Imaging of renal cancer using positron emission tomography with 2-deoxy-2-(18F)-fluoro-D-glucose: pilot animal and human studies.
Wahl RL; Harney J; Hutchins G; Grossman HB
J Urol; 1991 Dec; 146(6):1470-4. PubMed ID: 1942320
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of FDG PET in patients with cervical cancer.
Sugawara Y; Eisbruch A; Kosuda S; Recker BE; Kison PV; Wahl RL
J Nucl Med; 1999 Jul; 40(7):1125-31. PubMed ID: 10405131
[TBL] [Abstract][Full Text] [Related]
12. Experimental study for cancer diagnosis with positron-labeled fluorinated glucose analogs: [18F]-2-fluoro-2-deoxy-D-mannose: a new tracer for cancer detection.
Fukuda H; Matsuzawa T; Abe Y; Endo S; Yamada K; Kubota K; Hatazawa J; Sato T; Ito M; Takahashi T; Iwata R; Ido T
Eur J Nucl Med; 1982; 7(7):294-7. PubMed ID: 6981508
[TBL] [Abstract][Full Text] [Related]
13. The potential of 2-deoxy-2[18F]fluoro-D-glucose (FDG) for the detection of tumor involvement in lymph nodes.
Wahl RL; Kaminski MS; Ethier SP; Hutchins GD
J Nucl Med; 1990 Nov; 31(11):1831-5. PubMed ID: 2230996
[TBL] [Abstract][Full Text] [Related]
14. Decision logic for retreatment of asymptomatic lung cancer recurrence based on positron emission tomography findings.
Frank A; Lefkowitz D; Jaeger S; Gobar L; Sunderland J; Gupta N; Scott W; Mailliard J; Lynch H; Bishop J
Int J Radiat Oncol Biol Phys; 1995 Jul; 32(5):1495-512. PubMed ID: 7635795
[TBL] [Abstract][Full Text] [Related]
15. Initial experience in small animal tumor imaging with a clinical positron emission tomography/computed tomography scanner using 2-[F-18]fluoro-2-deoxy-D-glucose.
Tatsumi M; Nakamoto Y; Traughber B; Marshall LT; Geschwind JF; Wahl RL
Cancer Res; 2003 Oct; 63(19):6252-7. PubMed ID: 14559811
[TBL] [Abstract][Full Text] [Related]
16. [
Kollberg P; Almquist H; Bläckberg M; Cwikiel M; Gudjonsson S; Lyttkens K; Patschan O; Liedberg F
Scand J Urol; 2017 Aug; 51(4):308-313. PubMed ID: 28532260
[TBL] [Abstract][Full Text] [Related]
17. Qualitative [18F]FDG positron emission tomography in primary breast cancer: clinical relevance and practicability.
Scheidhauer K; Scharl A; Pietrzyk U; Wagner R; Göhring UJ; Schomäcker K; Schicha H
Eur J Nucl Med; 1996 Jun; 23(6):618-23. PubMed ID: 8662094
[TBL] [Abstract][Full Text] [Related]
18. Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma.
Gritters LS; Francis IR; Zasadny KR; Wahl RL
J Nucl Med; 1993 Sep; 34(9):1420-7. PubMed ID: 8355058
[TBL] [Abstract][Full Text] [Related]
19. [Value of dual-phase (18)F-FDG PET/CT in preoperative staging of bladder cancer].
Li H; Wu H; Wang Q; Han Y; Wang Q
Nan Fang Yi Ke Da Xue Xue Bao; 2014 Apr; 34(4):500-3. PubMed ID: 24752096
[TBL] [Abstract][Full Text] [Related]
20. FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer.
Swinnen G; Maes A; Pottel H; Vanneste A; Billiet I; Lesage K; Werbrouck P
Eur Urol; 2010 Apr; 57(4):641-7. PubMed ID: 19477579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
